FDA Brief

Warning letters Food

FDA warning letter to

Nutratech, LLC

High riskIssued Jun 4Posted Jul 14Human Foods Program

FDA cited Nutratech, LLC for manufacturing violations and an undeclared allergen in dietary supplements.

What happened

FDA inspected Nutratech, LLC's Phoenix, NY facility from September 22 through October 15, 2025 and issued a Form FDA 483, a list of inspection observations. FDA found significant violations of current good manufacturing practice (CGMP), the rules for how dietary supplements are made, including poor hand hygiene, dirty production areas and equipment, missing product specifications, incomplete manufacturing and batch records, and unresolved complaints. FDA also reviewed labels and found a product that contained a major food allergen but did not declare it.

What FDA found

  1. Employees did not follow hygienic practices, including not washing or sanitizing arms that touched ready-to-eat powder, having blocked handwashing stations, wearing jewelry and street clothes, and not correcting an ill employee.

    21 CFR 111.10(b)
  2. Production areas and component storage were not clean or sanitary, with dried residues, cobwebs, broken ceiling tiles, and open or exposed components.

    21 CFR 111.15(b)
  3. Equipment and utensils were not clean or suitably designed, including dirty scoops and a blender with compacted powder residue, and cardboard and a cracked non-food-grade box were used near production.

    21 CFR 111.27(a)
  4. The company did not establish required product specifications for identity, purity, strength, and composition for certain dietary supplement products.

    21 CFR 111.70(e)
  5. Master manufacturing records and batch production records lacked required process-control instructions and details such as equipment identity, cleaning times, yields, and monitoring results.

    21 CFR 111.210(h)(3); 21 CFR 111.260(b),(c),(f),(g)
  6. A product label failed to declare a major food allergen contained in the product.

    section 403(w) of the Act [21 U.S.C. 343(w)]

What FDA wants

FDA asks Nutratech to notify it in writing within 15 working days of the specific steps taken to address the violations, include an explanation and documentation to prevent recurrence, and state any reason and timeframe if corrections cannot be completed in that time.

Who should pay attention

  • brands that buy finished dietary supplements from Nutratech
  • contract manufacturers of powdered dietary supplements
  • companies that depend on supplier CGMP records and allergen labels

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk